Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
ProstACT Global
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
- NCT06520345 ↗
- Recruiting
- Telix Pharmaceuticals (Innovations) Pty Limited
- Standard
We haven't built an HCP commentary report on ProstACT Global (177Lu-TLX591, enzalutamide and 2 more in Metastatic Castration-resistant Prostate Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ProstACT Global so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 9 | |
| YouTube | 7 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination With Standard of Care Versus Standard of Care Alone in Patients With PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously After Androgen Receptor Pathway Inhibitor Treatment
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- 177Lu-TLX591; Enzalutamide; Abiraterone; Docetaxel
- Arms
- 177Lu-TLX591 + Enzalutamide or Abiraterone or Docetaxel · Experimental
- Control Arm (Enzalutamide or Abiraterone or Docetaxel) · Active comparator
- Enrollment
- 520 (estimated)
- Primary outcomes
- Radiographic Progression-free Survival
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
- Start
- Jul 26, 2024
- Primary completion
- Dec 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06520345 · updated Jul 21, 2026